Showing results (71-80 of 378) with videos related to
Sort By:
Pageof 38
Journal of Biopharmaceutical Statistics|December 7, 2006
Duffy-Santner confidence intervals for the two-stage three-outcome designAlfred F Furth, Daniel J SargentJournal of the National Cancer Institute|November 4, 2010
Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk predictionStuart G Baker, Daniel J SargentChinese Clinical Oncology|January 8, 2017
Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trialsLindsay A Renfro, Daniel J SargentCancers|November 7, 2020
Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical TrialsJennifer G Le-Rademacher, Shauna Hillman, Elizabeth Storrick, et al.European Journal of Cancer (Oxford, England : 1990)|January 17, 2012
Effect of cigarette smoking on quality of life in small cell lung cancer patientsJun Chen, Yingwei Qi, Jason A Wampfler, et al.Blood Advances|June 8, 2019
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)Jun Yin, Betsy LaPlant, Geoffrey L Uy, et al.Statistics in Medicine|October 13, 2005
An adaptive dose-finding design incorporating both toxicity and efficacyWei Zhang, Daniel J Sargent, Sumithra MandrekarJournal of Biopharmaceutical Statistics|April 23, 2009
Current issues in oncology drug development, with a focus on Phase II trialsDaniel J Sargent, Jeremy M G TaylorSeminars in Oncology|August 4, 2011
Statistical considerations for the next generation of clinical trialsWenting Wu, Qian Shi, Daniel J SargentStatistical Methods in Medical Research|February 21, 2008
Surrogate endpoint validation: statistical elegance versus clinical relevanceEm Green, G Yothers, Daniel J SargentPageof 38